Back to Search Start Over

Prognosis and immune response of a cuproptosis-related lncRNA signature in low grade glioma.

Authors :
Xu Y
Wang C
Li S
Zhou H
Feng Y
Source :
Frontiers in genetics [Front Genet] 2022 Oct 21; Vol. 13, pp. 975419. Date of Electronic Publication: 2022 Oct 21 (Print Publication: 2022).
Publication Year :
2022

Abstract

Cuproptosis is a newly discovered new mechanism of programmed cell death, and its unique pathway to regulate cell death is thought to have a unique role in understanding cancer progression and guiding cancer therapy. However, this regulation has not been studied in low grade glioma (LGG) at present. In this study, data on low grade glioma patients were downloaded from the TCGA database. We screened the genes related to cuproptosis from the published papers and confirmed the lncRNAs related to them. We applied univariate/multivariate, and LASSO regression algorithms, finally identified 11 lncRNAs for constructing prognosis prediction models, and constructed a risk scoring model. The reliability and validity test of the model indicated that the model could well distinguish the prognosis and survival of LGG patients. Furthermore, the analyses of immunotherapy, immune microenvironment, as well as functional enrichment were also performed. Finally, we verified the expression of these six prognostic key lncRNAs using real-time polymerase chain reaction (RT-PCR). In conclusion, this study is the first analysis based on cuproptosis-related lncRNAs in LGG and aims to open up new directions for LGG therapy.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Xu, Wang, Li, Zhou and Feng.)

Details

Language :
English
ISSN :
1664-8021
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in genetics
Publication Type :
Academic Journal
Accession number :
36338998
Full Text :
https://doi.org/10.3389/fgene.2022.975419